Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML).

Abstract

10017 Background: Bosutinib is a tyrosine kinase inhibitor (TKI), approved for adults with Philadelphia Chromosome (Ph+) CML; at the standard initial dose of 400 mg/day in ND patients, and 500 mg/day in resistant/intolerant (R/I) patients, administered orally once daily (QD) with food. Compared to the TKIs already approved in pediatrics, bosutinib has a different tolerability profile, and preclinical data suggest that longitudinal growth is potentially less impaired. Study NCT04258943 is an international, open-label, phase I/II trial, sponsored by the Erasmus Medical Center and the Children's Oncology Group, and funded by Pfizer Inc. The phase II arm enrolled ND patients, as well as R/I ones. The latter are not included in this analysis. Methods: ND patients aged 1-18 years with chronic phase CML, without evidence for organ toxicities, were enrolled. Main exclusion criteria included known T315I or V299L BCR-ABL1 mutations, and use of proton pump inhibitors and CYP3A inducers/inhibitors. The primary objectives of the phase II part of the study were to assess the safety and pharmacokinetics (PK) of bosutinib at the recommended phase II dose, which is body surface area adjusted, and consists of 300 mg/m2 QD for ND patients (max 500 mg/day), as determined in the phase I part of the study. Based on regulatory authorities requirements, at least 35 patients have to be enrolled in phase II, with a total of 50-60 patients in phase I and II combined. This allows for pooled AE rates to be estimated with a maximum standard error of 0.071 and 0.065, respectively. Results: On 20/12/2022, 25 ND patients were screened, and 24 were enrolled: 15 males, median age 13 years (range: 5-17). The median follow up was 14 (range: 0.9-31) months. The most common non-hematological adverse events (AEs) were diarrhea (n = 16, Grade (Gr) ≤ 2 = 13), abdominal pain (n = 10, Gr ≤ 2 = 10), and nausea/vomiting (n = 8/8, Gr ≤ 2 = 7/8). Most common hematological AEs included platelet count decrease (n = 11, Gr ≤ 2 = 5), and anemia (n = 10, Gr ≤ 2 = 4). At 6 and 12 months, the cumulative incidence of Major Cytogenetic Response (MCyR) was 85% (95%CI 49%-96%) and 92.5% (95%CI 39%-99%), while for Complete CyR it was 77% (47%-91%) and 88.3% (95%CI 55%-98%), and for Major Molecular Response it was 23% (95%CI 7%-46%) and 30% (95%CI 10%-54%), respectively. Three patients permanently discontinued bosutinib due to intolerance, four due to unsatisfactory response per investigator’s judgment, 17 were still on treatment at time of dataset lock. Conclusions: Bosutinib was well tolerated, despite common grade 1-2 gastrointestinal AEs. The preliminary efficacy seems comparable to published data from other second generation TKIs in children and to ND adult patients treated with bosutinib. Clinical trial information: NCT04258943 .